Skip to content

EV / EBITDA at other companies

Procter & Gamble logo
Procter & GamblePG
15×-3.6×
Johnson & Johnson logo
Johnson & JohnsonJNJ
18.8×+4.2×
HRO
HarrowHROW
70.8×-139×
Cencora logo
CencoraCOR
18.6×+2.4×
Bausch Health Companies logo
Bausch Health CompaniesBHC
12×+3.9×
Cardinal Health logo
Cardinal HealthCAH
16.9×+4.4×

Other financials

Income statement

See full
Revenue$281.6M-5.0%
Gross profit$146.3M-13.9%
Operating income$75.5M-14.6%
Net income$53.9M+7.6%
EPS (diluted)$1.13+11.9%

Balance sheet

See full
Cash & equivalents$63.9M-34.8%
Total debt$1.0B-0.2%
Total equity$1.9B+2.9%
Total assets$3.5B+2.7%

Cash flow

See full
Operating cash flow$42.8M-30.7%
CapEx$5.2M+49.8%
Free cash flow$37.6M-35.5%

Valuation

See full
Market cap$2.18B-34.1%
Enterprise value$3.16B-27.3%
P/E11.5×-4.0×
P/S-0.9×

Profitability

See full
Gross margin54.7%-1.1pp
Operating margin28.4%-1.2pp
Net margin17.5%-1.4pp
FCF margin22.6%+1.3pp

Returns & leverage

See full
Return on equity10.2%-2.1pp
Debt / equity0.6×0.0×
Current ratio3.6×-0.6×

Where this comes from

Calculated from Prestige Consumer Healthcare’s reported figures.

Based on the most recent quarter.

The official record: Prestige Consumer Healthcare’s 10-K, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prestige Consumer Healthcare's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prestige Consumer Healthcare's EV / EBITDA?
Prestige Consumer Healthcare (PBH) reported EV / EBITDA of 11.1× in Q1 2026.
How has Prestige Consumer Healthcare's EV / EBITDA changed year-over-year?
Prestige Consumer Healthcare's EV / EBITDA decreased by 21.7% year-over-year, from 14.2× to 11.1×.
What is the long-term trend for Prestige Consumer Healthcare's EV / EBITDA?
Over 5 years (2021 to 2026), Prestige Consumer Healthcare's EV / EBITDA has grown at a -0.3% compound annual growth rate (CAGR), from 11.3× to 11.1×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.